XLRN - Acceleron Pharma Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
42.00
-0.33 (-0.78%)
At close: 4:00PM EDT

42.00 0.00 (0.00%)
After hours: 4:25PM EDT

Stock chart is not supported by your current browser
Previous Close42.33
Open42.24
Bid41.99 x 1100
Ask42.02 x 1000
Day's Range41.66 - 42.74
52 Week Range37.01 - 59.59
Volume163,573
Avg. Volume303,371
Market Cap2.213B
Beta (3Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-2.76
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.82
Trade prices are not sourced from all markets
  • Are Insiders Selling Acceleron Pharma Inc. (NASDAQ:XLRN) Stock?
    Simply Wall St.8 days ago

    Are Insiders Selling Acceleron Pharma Inc. (NASDAQ:XLRN) Stock?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Business Wire27 days ago

    Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today it has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept. The Company now expects to report top-line results during the first quarter of 2020. “We’re thrilled with PULSAR’s rapid enrollment over the past 12 months, which underscores the urgency for new therapeutic options for patients with PAH,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron.

  • Acceleron Pharma Inc. (NASDAQ:XLRN): Financial Strength Analysis
    Simply Wall St.last month

    Acceleron Pharma Inc. (NASDAQ:XLRN): Financial Strength Analysis

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Acceleron Pharma Inc...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of XLRN earnings conference call or presentation 9-May-19 9:00pm GMT

    Q1 2019 Acceleron Pharma Inc Earnings Call

  • Business Wirelast month

    Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis, PhD, is retiring from his position on its Board of Directors and will continue to serve the organization in an advisory capacity as Director Emeritus. “Tom co-founded Acceleron in 2003 and has been on the Board from day one,” said Francois Nader, MD, Chairman of Acceleron Pharma. “During this period, Tom’s unparalleled scientific instincts and acumen were instrumental in turning a belief in the promise of a fundamental biological pathway into a company on the verge of delivering its first product to patients.

  • Celgene & Acceleron's BLA for Luspatercept Accepted by FDA
    Zacks2 months ago

    Celgene & Acceleron's BLA for Luspatercept Accepted by FDA

    Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.

  • Celgene (CELG) Presents Data on Pipeline Candidates at ASCO
    Zacks2 months ago

    Celgene (CELG) Presents Data on Pipeline Candidates at ASCO

    Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.

  • Here's Another Checkmark For Bristol's Looming Celgene Takeover
    Investor's Business Daily2 months ago

    Here's Another Checkmark For Bristol's Looming Celgene Takeover

    Shares of biotech company Celgene rose Tuesday after the FDA accepted its application for an Acceleron Pharma-partnered anemia treatment in beta thalassemia and some blood cancers.

  • Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
    Business Wire2 months ago

    Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia

    Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational erythroid maturation agent, for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. The FDA has granted Priority Review to this BLA for the evaluation of the beta-thalassemia indication and set a Prescription Drug User Fee Act (PDUFA), or target action, date of December 4, 2019.

  • Geron Stock Up More Than 50% in 2019 So Far: Here's Why
    Zacks2 months ago

    Geron Stock Up More Than 50% in 2019 So Far: Here's Why

    Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

  • Business Wire2 months ago

    Acceleron to Present at the UBS Global Healthcare Conference

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the UBS Global Healthcare Conference on Monday, May 20th, 2019 at 11:00 a.m. EDT in New York, NY. A live audio webcast will be available on the Investors/Media page of the Company's website at www.acceleronpharma.com. Acceleron is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.

  • Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates

    Acceleron (XLRN) delivered earnings and revenue surprises of -10.45% and -24.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Acceleron: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 74 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...

  • Business Wire2 months ago

    Acceleron Reports First Quarter 2019 Operating and Financial Results

    – Luspatercept Biologics License Application and Marketing Authorization Application submitted in April 2019 –

  • Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
    Zacks2 months ago

    Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

    Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

  • 5 Must-Buy Stocks Ahead of Q1 Earnings Amid Market Volatility
    Zacks2 months ago

    5 Must-Buy Stocks Ahead of Q1 Earnings Amid Market Volatility

    First-quarter 2019 earnings results so far are better than expected.

  • Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?
    Zacks3 months ago

    Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?

    Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).

  • Telenav (TNAV) to Report Q3 Earnings: What's in the Offing?
    Zacks3 months ago

    Telenav (TNAV) to Report Q3 Earnings: What's in the Offing?

    For the fiscal third quarter, Telenav (TNAV) expects total revenues between $49 million and $53 million, while net loss is anticipated to be $7 million-$9 million.

  • Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?
    Zacks3 months ago

    Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?

    Following the U.S.-commercial launch of Epidolex last November, GW Pharmaceuticals (GWPH) continues to see an uptick from the same.

  • Business Wire3 months ago

    Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019

    Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Thursday, May 9, 2019 at 5:00 p.m. EDT to discuss its first quarter 2019 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.

  • Here’s What Hedge Funds Think About Acceleron Pharma Inc (XLRN)
    Insider Monkey3 months ago

    Here’s What Hedge Funds Think About Acceleron Pharma Inc (XLRN)

    The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]

  • Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales
    Zacks3 months ago

    Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales

    Celgene (CELG) beats on earnings and sales in the first quarter of 2019.

  • Business Wire3 months ago

    Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia

    Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. Luspatercept is an investigational erythroid maturation agent that regulates late-stage red blood cell maturation.